Mometasona Viso Farmacéutica (Mometasone Furoate)

Mometasone furoate works by binding to intracellular glucocorticoid receptors. This complex alters gene transcription, leading to decreased production of pro‑inflammatory cytokines, inhibition of phospholipase A2, and reduced migration of inflammatory cells. The overall effect is a marked reduction in skin inflammation, edema and pruritus.

The specific dosing regimen for Mometasona Viso Farmacéutica is determined by the prescribing healthcare professional based on the severity of the condition, the area of skin involved, patient age and other clinical factors. Patients should follow the prescriber’s instructions and not alter the amount or frequency without medical advice.

Safety data for topical mometasone furoate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider before starting treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will request trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Mometasone furoate is a high‑potency class III topical corticosteroid, offering stronger anti‑inflammatory activity than lower‑potency agents such as hydrocortisone, but less potency than class I steroids like clobetasol. Compared with betamethasone dipropionate, another class III steroid, mometasone often provides similar efficacy with a favorable safety profile when used as directed.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme heat. Keep the container tightly closed when not in use and out of reach of children.

Apply a thin layer of the cream or ointment to the clean, dry affected skin area, usually once or twice daily as prescribed. Gently rub it in until it disappears. Wash hands before and after application, unless the hands are the treatment site.

Serious risks include hypothalamic‑pituitary‑adrenal (HPA) axis suppression with extensive use, skin atrophy or thinning, and secondary infections (bacterial, fungal or viral) of the treated area. Patients should report signs of systemic corticosteroid effects, unusual skin changes or infections to their healthcare provider promptly.

The product should be avoided in individuals with known hypersensitivity to mometasone furoate or any excipients, in untreated skin infections of bacterial, viral or fungal origin, and in patients where systemic corticosteroid therapy is contraindicated. Use in children under two years of age is generally not recommended without specialist guidance.